CTMX FY2021 SEC EDGAR DEF 14A

CytomX Therapeutics, Inc. CEO pay ratio

The CEO earned $4.3M in FY2021 against median worker pay of $206,639 · Chemicals & Pharmaceuticals.

State
DE
Filing date
2022-04-27
Industry
Chemicals & Pharmaceuticals
Fiscal year
FY2021

Data updated August 2026

Subscribe to CytomX Therapeutics, Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
21:1
Below Average (Scale: 0–1000:1)
CEO pay
$4.3M
Median worker
$206,639

Latest filing FY2021. This company's newest DEF 14A on file is for FY2021, not FY2025, so the figures on this page are from that earlier year and are not ranked against the FY2025 industry benchmark. Industry pages mark issuers like this one with a "Latest filing" label.

Answer first

CytomX Therapeutics, Inc. reported a 21:1 CEO-to-worker pay ratio in FY2021 - at or below the Chemicals & Pharmaceuticals median of 42:1 across 168 filers.

Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Pay ratio
21:1
FY2021 disclosed
CEO total
$4.3M
Summary Compensation Table total
Median worker
$206,639
Dodd-Frank median employee

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2021

A component-level pay breakdown is not reported in CytomX Therapeutics, Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
21:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$4.3M
Companies in Industry
168
vs. Industry Median
Below

CytomX Therapeutics, Inc.: near-parity Item 402(u) ratio

CytomX Therapeutics, Inc. stamps FLOOR · ELITE-MED at 21:1 against $206,639 median worker pay in FY2021. the CEO earned 21× the median employee ($206,639) in FY2021.

At $206,639 median worker pay, the FLOOR stamp is near pay-parity territory under MID$ CEO total.

CEO Total Pay

$4.3M

FY2021 Summary Compensation, below median

Pay Ratio

21:1

Below typical

What FY2021 shows for CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc. stamps FLOOR · ELITE-MED at 21:1 against $206,639 median worker pay in FY2021. The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; CytomX Therapeutics, Inc.'s $4.3M CEO total is at or below the $7.9M industry median CEO pay.

CytomX Therapeutics, Inc. stamps FLOOR · MID$ · ELITE-MED; grant-date fair value (not realized pay) is what the DEF 14A reports. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2021

Total Compensation
$4.3M
Median Employee Pay
$206,639
Pay Ratio
21:1
Filing Date
2022-04-27

Company Info

Ticker
CTMX
CIK
1501989
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
DE
SEC EDGAR DEF 14A for CIK 1501989, FY2021. Informational only, not investment advice. Verify on EDGAR.

Read with CytomX Therapeutics, Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps FLOOR · MID$ · ELITE-MED.

Data sourced from SEC EDGAR DEF 14A for CytomX Therapeutics, Inc. (CIK 1501989), FY2021. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.